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Abstract
Background: MYRIAD (My Resilience in Adolescence) is a superiority, parallel group, cluster randomised controlled
trial designed to examine the effectiveness and cost-effectiveness of a mindfulness training (MT) programme,
compared with normal social and emotional learning (SEL) school provision to enhance mental health, social-
emotional-behavioural functioning and well-being in adolescence. The original trial protocol was published in Trials
(accessible at https://doi.org/10.1186/s13063-017-1917-4). This included recruitment in two cohorts, enabling the
learning from the smaller first cohort to be incorporated in the second cohort. Here we describe final amendments
to the study protocol and discuss their underlying rationale.
Methods: Four major changes were introduced into the study protocol: (1) there were changes in eligibility criteria,
including a clearer operational definition to assess the degree of SEL implementation in schools, and also new
criteria to avoid experimental contamination; (2) the number of schools and pupils that had to be recruited was
increased based on what we learned in the first cohort; (3) some changes were made to the secondary outcome
measures to improve their validity and ability to measure constructs of interest and to reduce the burden on school
staff; and (4) the current Coronavirus Disease 2019 (SARS-CoV-2 or COVID-19) pandemic both influences and makes
it difficult to interpret the 2-year follow-up primary endpoint results, so we changed our primary endpoint to 1-year
follow-up.
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Discussion: These changes to the study protocol were approved by the Trial Management Group, Trial Steering
Committee and Data and Ethics Monitoring Committees and improved the enrolment of participants and quality of
measures. Furthermore, the change in the primary endpoint will give a more reliable answer to our primary
question because it was collected prior to the COVID-19 pandemic in both cohort 1 and cohort 2. Nevertheless, the
longer 2-year follow-up data will still be acquired, although this time-point will be now framed as a second major
investigation to answer some new important questions presented by the combination of the pandemic and our
study design.
Trial registration: International Standard Randomised Controlled Trials ISRCTN86619085. Registered on 3 June
2016.
Keywords: Adolescence, Schools, Resilience, Mindfulness, Depression, Prevention, Protocol update
Background
This update relates to the study protocol for ‘The effect-
iveness and cost-effectiveness of a mindfulness training
programme in schools compared with normal school
provision (MYRIAD): study protocol for a randomised
controlled trial [1]’.
Mindfulness-based approaches for adults are effective at
enhancing mental health [2], but few controlled trials have
evaluated their effectiveness or cost-effectiveness for
young people [3]. The primary aim of this trial is to evalu-
ate the effectiveness and cost-effectiveness of a mindful-
ness training (MT) programme to enhance mental health,
well-being and social-emotional-behavioural functioning
in adolescence. To address this main aim, the design was
a superiority parallel group cluster randomised controlled
trial in which schools (clusters) offering social and emo-
tional provision in line with good practice [4–6] were ran-
domised to either continue this provision (control arm) or
include MT in this provision (intervention arm). In gen-
eral, this study will contribute to establishing if MT is an
effective and cost-effective approach to promoting mental
health in adolescence at school settings.
Through learning in the conduct of the trial set up
and delivery, as well as the emergence of the coronavirus
disease 2019 (SARS-CoV-2 or COVID-19) pandemic,
the study team made several changes to the study proto-
col. This protocol update supplements the original study
protocol1 and should be read in conjunction with it.
Methods/design
Four major changes were made to the original study
protocol [1]. All of them were discussed and agreed by the
Trial Management Group and the Trial Steering Commit-
tee prior to their implementation, as well as receiving eth-
ical approval from the University of Oxford Medical
Sciences Inter-Divisional Research Ethics Committee.
Elaboration of the school eligibility criteria
In the main study protocol, only schools that offer social
and emotional learning (SEL) would be eligible for
participation. It was specified for cohort 1 that schools
were eligible for inclusion if their provision of SEL in-
cluded, among others, a ‘written SEL policy’. However,
for cohort 2, the ‘written SEL policy’ criterion was modi-
fied to ‘documentation denoting clear strategic planning
of SEL within the school’. The original protocol stated
that the initial eligibility criteria used in cohort 1 regard-
ing SEL might be modified if necessary in subsequent
cohorts. Experience in cohort 1 indicated that schools
do not always use the term ‘SEL policy’ to denote stra-
tegic planning of SEL. Moreover, in some cases, there
are schools that have an extensive, well-established and
well-documented SEL curriculum, indicative of a clear
structure and strategy around SEL, but do not have this
formalised as a school policy. Therefore, we reworded
this criterion as outlined above.
In the UK, many schools are often part of ‘academy
chains’. To avoid contamination between the trial arms,
if a school was part of an academy chain, normally, only
one school per academy would be recruited, and schools
already teaching mindfulness programmes were ex-
cluded from taking part in the trial for similar reasons.
Changes in the number of schools and pupils recruited
It was stated in the first version of the protocol that the
study would require 76 schools in total, with all year 7
and year 8 (or equivalent) students in each participating
school (roughly 25,000 in total) being invited to take
part in the baseline assessment. However, the project re-
cruited extra schools to allow for dropout at this cluster
level, predicting around 4 schools per study arm to drop
put.
On the other hand, it was established that all partici-
pating schools randomised to MT would have to agree
to deliver the programme to at least three different clas-
ses within years 8 and/or 9 (or equivalent), in order to
have approximately 90 pupils in total per school to be
eligible to participate in the full trial. This would provide
6840 pupils to be eligible to participate in the full trial,
with the expectation that only 5700 would have provided
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parental consent or pupil assent, and around 4560 would
complete the 2-year follow-up assessment. These as-
sumptions were made based on data of two previous
feasibility studies [7, 8], expecting that in every class of
30 pupils, 25 of them would have consent/assent to par-
ticipate, and finally 20 of these would be followed up.
These conditions would allow 75 participants per school
proceeding to start full trial participation. However, as
this sampling approach yielded a lower number of pupils
in some schools in cohort 1, it was revised from three to
four classes or more per school where possible in the
second and larger cohort 2, with the aim to have ap-
proximately 100 pupils per school.
Changes in secondary measures
During the course of the study, but before any specific
data were collected, some changes were made to the sec-
ondary measures. The ‘Resistance to Peer Influence
Scale’ (RPIS) that measures peer relationships [9] was re-
moved after a pilot session completed with an Oxford-
based young person’s advisory group. The questions
were not easy for all pupils to understand, and it was felt
the number of questions was too many for the pupils to
complete in one school lesson.
When the project was first designed, the child-friendly
EuroQol five dimensions measure (EQ-5D-Y) of health-
related quality of life [10] was the best available measure
for health economics studies with youth, but not totally
suitable as it was adapted from an adult version of the
questionnaire. It was finally replaced with the ‘Child
Health Utility 9D’ (CHU-9D). The reason for making
this change is that the CHU-9D is now considered a bet-
ter scientific measure than the EQ-5-DY measure for
use in young people. This is because the CHU-9D was
developed using adolescents [11, 12], so it is a much bet-
ter measure to use in this population. The CHU-9D has
now been used in many studies and therefore there are
value datasets available to use for the scoring of Quality
of Life measures, allowing the calculation of quality-
adjusted life years (QALYs) for use in economic
evaluation.
In addition to the brief measure designed to assess risk
behaviours, additional questions on binge drinking that
were taken from the ESPAD study (http://www.espad.
org) were added to broaden the items. The student level
mindfulness practice and a pupil credibility assessment
of SEL and MT lessons were also gathered, as well as
two open questions about the possible existence of posi-
tive and negative experiences during or after the mind-
fulness lessons, as an opportunity to find out what the
pupils felt about SEL and the course.
In cohort 2 at the 2-year follow-up (T4), we decided
not to collect the teachers’ reports of the ‘Strengths and
Difficulties Questionnaire’ (SDQ) [13] and the
‘Behaviour Rating Inventory of Executive Function’
(BRIEF-2) [14]. The reason was to try to reduce the bur-
den on school staff who were under extraordinary pres-
sure managing the impact of the COVID-19 pandemic.
Moreover, this time-point was reframed in cohort 2 as a
second major study to answer important new questions
presented by the combination of the pandemic and our
study design.
Change of the primary endpoint to 1-year follow-up
The COVID-19 pandemic broke out in 2020, profoundly
affecting every aspect of life in the UK from 30th March
onwards. A nationwide lockdown started in March 2020,
and all schools were instructed to close from 20 March
2020 although some schools remained open to the chil-
dren of keyworkers and children deemed vulnerable by
the senior leadership team. UK schools, teachers and
children have all been affected in a range of ways, emo-
tionally, socially and educationally. In relation to the
MYRIAD trial, the pandemic broke out in the latter
phase of the trial. For cohort 1 (12 schools), we had suc-
cessfully completed all the data collection, so these data
are pre-COVID-19 and unaffected by the pandemic. For
the much larger cohort 2 (72 schools), the pandemic
broke after the main MT intervention and after the T1,
T2 and T3 data collection points, but before T4, the
time point originally specified for collection of the pri-
mary outcome data.
Clearly, the most significant impact of the pandemic is
therefore on the final primary outcome T4 data collec-
tion for cohort 2. Various scenarios have been consid-
ered, but all point to our cohort 2 T4 data collection
point being seriously compromised by incomplete and
poor quality data (e.g. the uncertainty about when/if
schools will return and might return partially, re-
searchers would not be able to go in the schools to ad-
minister the assessments due to social distancing issues,
etc.), which would put in doubt the validity and preci-
sion of the estimates. Moreover, the findings have to be
contextualised within the pandemic, and their
generalizability beyond these particular circumstances is
questionable. Therefore, there was an imperative to re-
vise the protocol to ensure we can answer the research
question we set out to answer originally.
Therefore, the primary endpoint will now be at 1-year
(T3) rather than 2-year (T4) follow-up. The main scien-
tific rationale for this is to enable us to ask the trial
question using our stated design, without our findings
being contingent on the pandemic and without our pri-
mary outcome data being seriously compromised. The
T3 1-year follow-up was collected prior to the pandemic,
in the same way across both trial arms. While this is a
protocol change, it does not affect the basic trial ques-
tion or design; it asks the main question at 1-year rather
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than 2-year follow-up. The original rationale for the 2
year follow-up being our primary endpoint was to ex-
tend as much as possible the time point to measure long
term effects of this universal MT programme [15]. In
this sense, changing the primary time point to T3 re-
duces the possibility of evaluating long term effects,
which is something relevant in the current state of the
field [3, 16] but with the counterpart of ensuring a reli-
able answer to our primary question. Nevertheless, the
longer T4 follow-up data will still be acquired for cohort
2, but this time-point will be secondary outcome, inter-
pretable only within the context of the issues above. The
sample size calculation did not state the timing of the
end point, so these calculations are equally valid for the
T3 follow-up as the T4 follow-up.
Conclusion
In order to improve the clarity of school eligibility cri-
teria, one criterion related to the description of provision
of SEL at schools was developed with more detail. In
addition, according to the conduct observed in cohort 1,
the necessary number of schools and pupils recruited
was extended to ensure an adequate sample size. Also,
to recognise the development of new and better mea-
sures and our own learning in cohort 1, some of the in-
struments were changed and new measures were
included. Moreover, to reduce the burden on school
staff, two teacher rated scales of pupils were removed.
Finally, because the pandemic put at risk the ability of
the study to answer the proposed questions using the
original primary endpoint, it was changed from 2-year
follow-up to 1-year follow-up. This change reduced the
possibility of assessing long term effects associated with
the programme. However, the 1-year follow-up assess-
ment eliminates the risk of data loss and confounding
because it is a pre-pandemic measurement.
Trial status
Recruitment of schools was completed in Autumn 2017.
The first cohort of schools (12) completed their 2-year
follow-up visits in January 2020. The second cohort of
schools (72) completed the 1-year follow-up of the pro-
ject during the Autumn term of 2019 with some schools
finishing in January 2020. The final 2-year follow-up was
planned to take place in Autumn 2020; however, due to
the outbreak of COVID-19, at the time of writing the
timing of this phase of data collection remain uncertain
and will be moved to a later time point.
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